Last reviewed · How we verify

Impavido — Competitive Intelligence Brief

Impavido (MILTEFOSINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antileishmanial [EPC]. Area: Rare Disease.

marketed Antileishmanial [EPC] RAC-alpha serine/threonine-protein kinase Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Impavido (MILTEFOSINE) — Knight Theraps. Impavido works by inhibiting the RAC-alpha serine/threonine-protein kinase, which is essential for the survival of Leishmania parasites.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Impavido TARGET MILTEFOSINE Knight Theraps marketed Antileishmanial [EPC] RAC-alpha serine/threonine-protein kinase 2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antileishmanial [EPC] class)

  1. Knight Theraps · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Impavido — Competitive Intelligence Brief. https://druglandscape.com/ci/miltefosine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: